Concepedia
Statistics
Publications
23
Citations
1K
H-Index
19
Active since
1982
Affiliations
AstraZeneca (United Kingdom)(Current)
AstraZeneca (United States)
AstraZeneca (Sweden)
Aston University
Wellcome Centre for Cell-Matrix Research
Ian L. Dale is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and drug discovery.
Top concepts
MedicinePharmacologyDrug DiscoveryBiochemistryTumor BiologyPharmacotherapyCell BiologyCancer ResearchNatural SciencesMedicinal Chemistry
Publications per year
1982–2024
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 147 citations · Full text
Azd5153 Exposure, Pathology, Pharmacotherapy +17
Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring, Huawei Chen, Alfred A. Rabow et al. · Nature Chemical Biology · 2016 · 134 citations · Full text
Medicinal Chemistry, Selective Bivalent Inhibitors, Medicine +3
Assessment of Cardiomyocyte Contraction in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Amy Pointon, Alexander R. Harmer, Ian L. Dale et al. · Toxicological Sciences · 2014 · 102 citations · Full text
Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells
Ian L. Dale, Andreas J. Gescher · International Journal of Cancer · 1989 · 59 citations
An evaluation of fluorescence polarization and lifetime discriminated polarization for high throughput screening of serine/threonine kinases
Ann Fowler, Denise Swift, Emma Longman et al. · Analytical Biochemistry · 2002 · 53 citations
Engineering, Biochemistry, High Throughput Screening +11
1–5 of 23